Advertisement

Gov. Jack Markell's office says plans by pharmaceutical company AstraZeneca PLC to eliminate 550 jobs at its U.S. headquarters in Delaware is not part of a plan to pull out of the state altogether.

Spokesman Brian Selander tells WDEL-AM that the layoffs are instead a shift of emphasis by the company.

The termination of psychiatric laboratory research in Delaware represents about one-third of the company's research and development work force in the state, where future R&D efforts will focus on shepherding drugs through clinical trials and regulatory approval.

AstraZeneca says its facilities in Boston will see some growth as employees transfer from other sites.

_________________

Information from WDEL-AM: www.wdel.com

Advertisement
Advertisement